GO
Loading...

Health Care Supplies

More

  • JNJ to pay $2.2 billion in US probe: Feds Monday, 4 Nov 2013 | 1:53 PM ET

    Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.

  • Lacks family wins victory to claim woman's cells Thursday, 8 Aug 2013 | 8:12 AM ET
    Multiphoton fluorescence image of cultured HeLa cells with a fluorescent protein targeted to the Golgi apparatus (orange), microtubules (green) and counterstained for DNA (cyan).

    The family of Henrietta lacks, whose immortal cells made billions in medical research, won an ethical victory when they were given some power over HeLa cell information.

  • Henry Schein's healthy results     Tuesday, 6 Aug 2013 | 2:48 PM ET

    Henry Schein is the world's largest health care products and services company for doctors, dentists, and vets, and the stock has been on a tear. Stanley Bergman, Henry Schein chairman and CEO, shares where he sees dental and health care headed.

  • J&J beats expectations as drugs, devices deliver Tuesday, 16 Jul 2013 | 7:50 AM ET

    Johnson & Johnson reported higher-than-expected earnings as strong sales of prescription drugs and medical devices more than offset anemic growth of its consumer products.

  • Plan-B for All—No Age Limits on Morning-After Pill Tuesday, 11 Jun 2013 | 10:17 AM ET

    Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.

  • Bristol and Merck Shares Surge on Cancer Drug News Monday, 3 Jun 2013 | 3:32 PM ET

    Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.

  • Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.

  • Johnson & Johnson's Stock Looks Too Healthy Wednesday, 1 May 2013 | 3:02 PM ET

    Johnson & Johnson's stock has gained 22 percent on the year and trades at a higher P/E ratio than its competitors. It is not a good buy now, but a great hold, TheStreet.com says.

  • Hospitals See Surge of Weapons in War on 'Superbugs' Monday, 29 Apr 2013 | 8:24 AM ET

    The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.

  • J&J Tops Estimates on Newer Medicine Growth Tuesday, 16 Apr 2013 | 8:16 AM ET

    The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.

  • Roger Parloff, Fortune senior editor, says businesses are sprouting in states like Colorado and Washington, where selling cannabis is now legal.

  • Obamacare Wellness Programs Could Raise Health Costs Thursday, 21 Feb 2013 | 12:31 PM ET

    If you smoke, you might have to pay thousands extra for employee-based health insurance under Obamacare starting next year.

  • First on CNBC: Cochlear Earnings     Monday, 4 Feb 2013 | 9:35 PM ET

    On a First on CNBC interview, Cochlear CEO Chris Roberts tells CashFlow about his company's products and plans for global expansion.

  • J&J Knew About Widespread Hip Implant Failures: Audit Wednesday, 23 Jan 2013 | 9:52 AM ET

    An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.

  • Pfizer Unit IPO Carries a Huge Price Tag Friday, 18 Jan 2013 | 8:17 AM ET

    Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.

  • Major Flu Outbreak Could Slow US Economy Further Thursday, 10 Jan 2013 | 12:00 AM ET

    One of the worst flu seasons in a decade is putting further strains on an already sluggish U.S. economy as companies get slammed with increased health care costs and lower productivity from widespread worker absences.

  • Big Pharma Bets on Obesity Drug Binge Thursday, 27 Dec 2012 | 2:18 AM ET

    As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.

  • The managing partner of Google's venture capital, Bill Maris,  says under-investment in health sciences is short-sighted.

  • DNA

    The goal is to enable physicians and pharmaceutical companies to use complex genetic data to tailor treatment on an individual basis, according to Mike Pellini, CEO of Foundation Medical.

  • Fungal Meningitis Death Toll Reaches 8     Tuesday, 9 Oct 2012 | 1:22 PM ET

    According to the CDC, the death toll has now reached 8 from a contaminated steroid used to treat back pain that came from a Massachusetts Compounding pharmacy. The next update from the CDC will be at 2PM EST today.

Most Popular Video

Wednesday, 16 Apr 2014 | 11:11 PM ET

Vasu Menon, VP, Group Wealth Management at OCBC Bank, describes why Asian shares are mixed on Thursday despite dovish comments from the Fed overnight.

Wednesday, 16 Apr 2014 | 9:13 PM ET

Ha Jiming, Vice Chairman, China at Goldman Sachs Private Wealth Management, says China needs structural reforms that can correct imbalances in its economy.

Wednesday, 16 Apr 2014 | 8:55 PM ET

Frank Appel , CEO at Deutsche Post DHL, sees "higher chances than risks" for its business in the mainland despite recent data pointing to a slowdown.